Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy

Publisher： Karger

E-ISSN： 1423-0232|82|5|298-304

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.5, 2012-04, pp. : 298-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 57-68

Karger

Access to resources Recommend Favorite

Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies

By Lièèvre Astrid   Laurent-Puig Pierre  

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 145-157

Future Medicine

Access to resources Recommend Favorite

Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 359-364

Karger

Access to resources Recommend Favorite

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials

By  

Oncology, Vol. 83, Iss. 5, 2012-08 ,pp. : 241-247

Karger

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite